Taiwan Expected To Approve Soon Nation's First Weight-loss Drug
This article was originally published in PharmAsia News
Executive SummaryTaiwan's Bureau of Pharmaceutical Affairs is expected to give the go-ahead to GlaxoSmithKline to market its Alli (orlistat) drug to people seeking to lose weight in Taiwain. The BPA has reviewed safety aspects of the drug, but an official warns potential patients need to remember Alliis a drug and should be handled with precaution. The official suggested GSK might have to provide an easy-to-read leaflet describing side effects of the drug and a requirement pharmacists explain its use. (Click here for more
You may also be interested in...
An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.
San Francisco-based digital health start-up Steady Health has launched the first "virtual" full-service diabetes clinic for patients in California. See what Henrik Berggren, CEO and founder of Steady Health, said about it here.
The first phase of a major trade agreement just signed by the US and China obliges the latter to implement a system linking pharma patent enforcement to marketing authorization procedures as well as to offer patent-term extensions.